Willow Reviews 2026: Pricing & Verdict

Willow offers GLP-1 medications through monthly subscription plans. No long-term contract is advertised, though users report difficulty canceling.

Willow also sells branded supplements (Metabolic Reset Kit, Protein Powder) at additional cost. Provider consultations and metabolic coaching are included in the subscription.

Pricing is mid-to-high for the telehealth GLP-1 market. Semaglutide at $299 per month matches MEDVi ($299) and Ellie MD ($299). Tirzepatide at $499 is significantly more expensive than MEDVi ($399) or Ellie MD ($379).

For context on standard dosing at these prices, see our semaglutide dosage chart and tirzepatide dosage chart.

The National Advertising Division (NAD) of BBB National Programs investigated Willow's marketing claims and found problems significant enough to refer the matter to state attorneys general.

What NAD found:

Willow made weight loss claims that NAD determined were not adequately supported by evidence. The specific claims included projected weight loss percentages and timelines that did not match the clinical evidence for the products being sold.

What this means:

NAD is a self-regulatory body, not a government agency. It cannot impose fines or force changes. When a company refuses to comply with NAD recommendations, the standard escalation is referral to the FTC or state attorneys general for potential enforcement action.

Willow's referral to state attorneys general signals that the company either disagreed with NAD's findings or did not adequately modify its advertising. This is a serious trust signal. Most legitimate telehealth companies cooperate with NAD proceedings.

For context, Zealthy faces a DOJ/FTC lawsuit. The telehealth GLP-1 market has significant regulatory scrutiny across multiple platforms.

Willow operated as Calibrate until 2024. The rebrand coincided with a period of negative reviews and operational complaints.

Calibrate launched as a "metabolic health" company positioning itself above simple weight loss platforms. The original model included a one-year membership ($1,595) with insurance coordination for brand-name GLP-1 drugs. When compounded GLP-1s became available at lower prices, Calibrate pivoted to direct-to-consumer compounded medications and rebranded as Willow.

The rebranding pattern is notable in the telehealth weight loss space. Companies accumulate negative reviews, rebrand, and restart their online reputation. The underlying operational issues often persist.

Calibrate's Trustpilot page accumulated complaints about medication delays, billing issues, and poor customer service. Willow's Trustpilot page shows similar complaint patterns. The rebrand changed the name but the operational problems carried over.

Willow's Trustpilot profile shows a 2.4/5 rating with 49% of reviews at one star. The complaint patterns are consistent across hundreds of reviews.

Medication delays. The most common complaint. Users report waiting weeks to months for medication shipments after payment. Some report paying for months of service without receiving medication. Delays are attributed to pharmacy issues, provider scheduling, and insurance processing.

Cancellation difficulties. Users report that canceling their subscription is difficult or impossible through normal channels. Common complaints: no cancel button in the app, customer service unresponsive to cancellation requests, continued billing after requesting cancellation.

Provider access. Despite advertising ongoing provider access, users report long wait times for provider responses and difficulty reaching their assigned clinician. Some report being reassigned to new providers without notice.

Billing issues. Users report being charged after cancellation, charges for months when no medication was delivered, and difficulty obtaining refunds for services not rendered.

Positive reviews exist. Some users report genuine weight loss success, helpful coaching, and functional medication delivery. The positive experiences appear legitimate. The problem is consistency: the platform works well for some patients and fails badly for others.

For platforms with stronger reviews, see our MEDVi review (Trustpilot 4.0/5).

Willow has the weakest trust profile in this comparison. The NAD referral, 49% one-star Trustpilot rate, and rebrand from Calibrate represent more red flags than any competing platform. Pricing is average-to-high with no offsetting advantage in service quality.

For patients who prioritize trust and reliability, MEDVi (4.0 Trustpilot, 24/7 provider messaging) or Ro Body (established brand, insurance options) are stronger choices. For budget-conscious patients, Hims or Zealthy offer lower starting prices.

For a broader view of legitimate peptide sourcing, see our where to buy peptides 2026 guide.

Willow may work if you:

• Want both compounded and brand-name GLP-1 options on one platform
• Value the coaching/metabolic health approach (if it functions as advertised)
• Are comfortable with the current trust profile and willing to accept delivery variability

Willow is not recommended if you:

• Need reliable, on-time medication delivery (medication delays are the top complaint)
• Want easy cancellation if the service does not meet expectations
• Are concerned about the NAD referral and unsubstantiated marketing claims
• Want the best value for your money (tirzepatide at $499 is $100-120 more than competitors)
• Prefer a platform with a strong review history (49% one-star is among the worst in the market)

The risk-reward calculation is unfavorable. Willow charges average-to-premium prices while delivering below-average reliability and customer service. Multiple alternative platforms offer the same medications with stronger track records.